Artwork

Content provided by MedPage Today. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MedPage Today or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !

What to Know About the Factor XIa Inhibitors on the Horizon

17:53
 
Distribuie
 

Manage episode 403459834 series 2546758
Content provided by MedPage Today. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MedPage Today or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
A novel class of antithrombotic medication, the factor XIa inhibitors, has had a rocky start but is powering through phase III trials, which are now underway. MedPage Today sat down to discuss the novel agents with Graeme Hankey, MBBS, MD, of the University of Western Australia School of Medicine & Pharmacology and Sir Charles Gairdner Hospital, both in Perth, Australia. He’s also co-chair of the Secondary Stroke Prevention Executive Committee and the Program Executive Council for the Librexia trial program for one of the factor XIa agents, milvexian. Episode produced and hosted by Crystal Phend. Sound engineering by Greg Laub.
  continue reading

70 episoade

Artwork
iconDistribuie
 
Manage episode 403459834 series 2546758
Content provided by MedPage Today. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MedPage Today or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
A novel class of antithrombotic medication, the factor XIa inhibitors, has had a rocky start but is powering through phase III trials, which are now underway. MedPage Today sat down to discuss the novel agents with Graeme Hankey, MBBS, MD, of the University of Western Australia School of Medicine & Pharmacology and Sir Charles Gairdner Hospital, both in Perth, Australia. He’s also co-chair of the Secondary Stroke Prevention Executive Committee and the Program Executive Council for the Librexia trial program for one of the factor XIa agents, milvexian. Episode produced and hosted by Crystal Phend. Sound engineering by Greg Laub.
  continue reading

70 episoade

Wszystkie odcinki

×
 
Loading …

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

 

Ghid rapid de referință

Listen to this show while you explore
Play